Our commitment to AI is integrated across our entire drug development process. One of the most exciting examples is the development and leveraging of virtual patient populations, more commonly (and fondly) known as “digital twins.” Sanofi’s Global Head of Translational Disease Modeling Thomas Klabunde explains how digital “twinning” works and how it is helping accelerate the R&D process across asthma and other immune-mediated diseases. Read more: http://spkl.io/6040471ZA
Amazing. This has the power to make a real difference👏
Fascinating! Sanofi's approach with digital twins in drug development is groundbreaking and promises to revolutionize the field.
Love this
Interesting!
Interesting!
📌 Fascinating, thought-provoking insights! Through significant reading on the commercial applications of 'synthetic research respondents' (as similar concept) we know there are challenges using AI at present, because LLM AI tools like ChatGPT are biased in a number of ways (e.g. wanting to please the user). However, modelling patients this way, created with real-world patient variables, appears to be a novel approach with plenty going for it. Great post! 🚀